2018
The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up
Hecht R, Hiebert L, Spearman WC, Sonderup MW, Guthrie T, Hallett TB, Nayagam S, Razavi H, Soe-Lin S, Vilakazi-Nhlapo K, Pillay Y, Resch S. The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up. Health Policy And Planning 2018, 33: 528-538. PMID: 29529282, PMCID: PMC5894072, DOI: 10.1093/heapol/czy018.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisDeveloping CountriesHealth PlanningHepatitis BHepatitis CHumansPolicy MakingResource AllocationSouth Africa
2012
Financing vaccinations – The South African experience
Blecher MS, Meheus F, Kollipara A, Hecht R, Cameron NA, Pillay Y, Hanna L. Financing vaccinations – The South African experience. Vaccine 2012, 30: c79-c86. PMID: 22939027, DOI: 10.1016/j.vaccine.2012.04.042.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisHealth PolicyHumansImmunization ProgramsPneumococcal VaccinesRotavirus VaccinesSouth AfricaVaccinationConceptsNew vaccinesNew vaccinationsNational vaccination policyBurden of diseaseHealth Economic CriteriaNew generation vaccinesNational advisory groupDepartment of HealthRotavirus diarrheaPneumococcal diseaseVaccination policyVaccinationGeneration vaccinesVaccineGlobal guidelinesEarly introductionInitial donationNumber of livesDiseaseInternational expertsAdvisory GroupFivefold increaseHealthNational spendingMorbidity
2011
Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries
Resch S, Korenromp E, Stover J, Blakley M, Krubiner C, Thorien K, Hecht R, Atun R. Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries. PLOS ONE 2011, 6: e25310. PMID: 21998648, PMCID: PMC3187775, DOI: 10.1371/journal.pone.0025310.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-HIV AgentsChildCost-Benefit AnalysisDeveloping CountriesEmploymentHumansIncomeInvestmentsTime FactorsConceptsMiddle-income countriesAIDS treatmentProgram costsIncome countriesLarge health gainsAntiretroviral therapyHIV infectionOpportunistic infectionsGlobal FundLife careMedical treatmentAIDS diseaseTreatment programHealth gainsCurrent cohortTotal program costsTreatmentPatientsCohortInfectionCareEnd 2011Same periodEconomic benefitsLabor productivity effects